tirzepatide cardiovascular outcome Real-World Outcomes of Obesity Treatment With Versus Semaglutide in Non-Diabetic Adults In obese individuals without diabetes, tirzepatide was associated with a lower risk of cardiovascular events, especially incident HF Tirzepatide compared with semaglutide and

Additional lipid-lowering agents, such as ezetimibe or icosapent ethyl, may be considered in certain cases

Have you started a GLP-1 medication like Ozempic, Wegovy, Mounjaro, or Saxenda and noticed changes in your skin

AHK-Cu (Copper Tripeptide-3, INCI: Acetyl Tetrapeptide-3) is a synthetic copper peptide specifically developed for scalp and hair follicle applications

Safety concerns : Important risks associated with GLP-1 receptor agonists include pancreatitis, gallbladder disease, dehydration leading to acute kidney injury, hypoglycaemia (when used with insulin or sulfonylureas), and potential worsening of diabetic retinopathy with rapid glycaemic improvement

Free IGF-1 (unbound to BPs) is what actually activates receptors